KYTRIL
LOE ApproachingNDAORALTABLET
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL (granisetron) is an oral small-molecule 5-HT3 receptor antagonist indicated for prevention of nausea and vomiting in oncology and post-operative settings. Approved in 1995, it remains a standard-of-care antiemetic across multiple therapeutic contexts. The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.
LOE Approaching
As an established product approaching loss of exclusivity with moderate competitive pressure (30), the brand team likely focuses on retention and life-cycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
With zero linked job openings and approaching LOE, KYTRIL represents a mature, stable franchise suitable for professionals seeking predictable, established market experience rather than high-growth opportunity. Roles focus on protecting market share, managing generic competition, and optimizing commercial efficiency.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.